Evidence map›Paper›PMID 31891871›Full record

ArticleTranslational oncology2020

Is There an Independent Role of TERT and NF1 in High Grade Gliomas?

Evangelia Razis, Vassiliki Kotoula, Georgia-Angeliki Koliou, Kyriaki Papadopoulou, Eleni Vrettou, Eleni Giannoulatou, Ioannis Tikas, Stefanos V Labropoulos, Georgios Rigakos, Styliani Papaemmanoyil and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Association of human telomerase reverse transcriptase promoter mutation with unfavorable prognosis in glioma: A systematic review and meta-analysis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023
    Review
  2. Article
  3. Review
  4. Cancers · 2021
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Prognostic impact ofFrontiers in neurology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 3 countries.

Evangelia RazisThird Department of Medical Oncology, Hygeia Hospital, 4 Erithrou Stavrou St, Marousi, 15123 Athens, Greece. Electronic address: e.razis@hygeia.gr.
Vassiliki KotoulaDepartment of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, University Campus, Building 17B, 54006 Thessaloniki, Greece; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, University Campus, Building 17B, 54006 Thessaloniki, Greece.
Georgia-Angeliki KoliouSection of Biostatistics, Hellenic Cooperative Oncology Group, Athens, Greece.
Kyriaki PapadopoulouLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, University Campus, Building 17B, 54006 Thessaloniki, Greece.
Eleni VrettouDepartment of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, University Campus, Building 17B, 54006 Thessaloniki, Greece.
Eleni GiannoulatouVictor Chang Cardiac Research Institute, Lowy Packer Building, 405 Liverpool Street, Darlinghurst, NSW 2010, Australia; The University of New South Wales, Kensington, Sydney, NSW 2052, Australia.
Ioannis TikasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, University Campus, Building 17B, 54006 Thessaloniki, Greece.
Stefanos V LabropoulosThird Department of Medical Oncology, Hygeia Hospital, 4 Erithrou Stavrou St, Marousi, 15123 Athens, Greece.
Georgios RigakosThird Department of Medical Oncology, Hygeia Hospital, 4 Erithrou Stavrou St, Marousi, 15123 Athens, Greece.
Styliani PapaemmanoyilDepartment of Pathology, General Hospital G. Papanikolaou, Leof. Papanikolaou, Pilea Chortiatis, 57010 Thessaloniki, Greece.
Ourania RomanidouDepartment of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Periferiaki Odos, Nea Efkarpia, 56403 Thessaloniki, Greece.
Eugenia BourkoulaGeneKor Medical SA, Leof. Spaton 52, Gerakas, 153 44 Athens, Greece.
Panagiotis NomikosDepartment of Neurosurgery and Gamma Knife Radiosurgery, Hygeia Hospital, 4 Erithrou Stavrou St, Marousi, 15123 Athens, Greece.
Georgios IliadisRadiotherapy Department, Interbalkan European Medical Center, Asklipiou 10, Pilea Chortiatis 555 35, Thessaloniki, Greece.
George NasioulasGeneKor Medical SA, Leof. Spaton 52, Gerakas, 153 44 Athens, Greece.
Panagiotis SelviaridisFirst Department of Neurosurgery, AHEPA University General Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Kiriakidi 1, 546 21 Thessaloniki, Greece.
Konstantinos PolyzoidisFirst Department of Neurosurgery, AHEPA University General Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Kiriakidi 1, 546 21 Thessaloniki, Greece.
George FountzilasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, University Campus, Building 17B, 54006 Thessaloniki, Greece; Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; German Oncology Center, Avenue Nikis 1, 4108 Agios Athanasios, Limassol, Cyprus.
Aristotle University of Thessaloniki · GRHygeia Hospital · GRAHEPA University Hospital · GRAthens Medical Center · GRG. Papanikolaou General Hospital · GRHellenic Cooperative Oncology Group · GRInterbalkan Medical Center · GRPapageorgiou General Hospital · GRVictor Chang Cardiac Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh grade glioma molecular profiling is of particular interest in neurooncology. The role of telomerase reverse transcriptase (TERT) varies dependent upon other molecular parameters. We explored the role of TERT in 101 high-grade gliomas.

methodsA total of 101 patients (pts) with grade III-IV gliomas treated with standard of care and informative tumor genotypes were included in the present study. Of 55 genes targeted with the next-generation sequencing panel, mutations (muts) were found in 37; these were included in the analysis. TERT mut were tested with Sanger sequencing. MGMT promoter methylation status was determined by methylation specific PCR.

results270 mut were detected in 92/101 tumors (91.1%). TERT was the most frequently mutated gene (74.3%). IDH1/2 mut were mutually exclusive with mut in the neurofibromin 1 (NF1) gene. Mutated TERT was associated with wild-type (wt) IDH1/2 (p = 0.025). The 12-month overall survival (OS) rate was 74.3% (median OS: 22 months). Pts with TERT and NF1 wt had a median OS of 40.8 months, while among pts with NF1 wt/TERT mutant, the median OS was 18.5 months. NF1 and TERT mut univariately conferred shorter OS (HR = 3.19; p = 0.004 and HR = 2.28; p = 0.002). Upon multivariate analysis, mutated TERT showed marginal unfavorable prognostic significance for OS (p = 0.049), while NF1 lost its unfavorable significance (p = 0.151).

conclusionsTERT is herein proven to confer poor prognosis in high grade gliomas, independent of IDH and MGMT. NF1 seems to also confer poor prognosis although our small numbers do not allow for firm conclusions.

Identifiers

PMID31891871
PMCPMC6940679
OpenAlexW2997849382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.